The Multiple Myeloma Research Consortium (MMRC) announced today that data from 13 of its clinical trials and three from the Multiple Myeloma Research Foundation (MMRF) Genomics Initiative, which analyzes tissue samples from the MMRC tissue bank, have been selected for oral or poster presentations at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH) to be held in New Orleans from December 5-8, 2009.
“It is truly exciting to see how quickly the promise of the MMRC has come to fruition,” stated Kathy Giusti, founder and CEO of both the MMRF and the MMRC and a multiple myeloma patient. “To be a part of 16 abstracts shows us that the MMRC – which only began five years ago – has proven its ability to choose promising compounds from the beginning. While our Genomics Initiative is helping to build a model for personalized medicine, the MMRC continues to deliver on our commitment to bring the next generation of therapies to patients as quickly as possible.”
The abstracts became available for viewing last week on the American Society of Hematology website (www.hematology.org).
New research explores how omega-3 and omega-6 fatty acids may impact cancer rates